Jones Financial Companies Lllp Buys 166,006 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Jones Financial Companies Lllp dramatically increased its stake in Vaxcyte, Inc. by over 113,702.7%, now owning 166,152 shares valued at approximately $6.27 million.
• Several other institutional investors, including Rhumbline Advisers and PNC Financial Services Group, also raised their holdings in Vaxcyte during the first quarter, demonstrating growing interest in the company's stock.
• Vaxcyte recently reported earnings with a loss per share of ($1.22), missing estimates, yet analysts maintain a consensus price target of $121.75 with a general rating of "Buy."

Jones Financial Companies Lllp grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 113,702.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 166,152 shares of the company's stock after buying an additional 166,006 shares during the period. Jones Financial Companies Lllp owned approximately 0.13% of Vaxcyte worth $6,274,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rhumbline Advisers lifted its position in shares of Vaxcyte by 5.5% in the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock worth $6,843,000 after buying an additional 9,416 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Vaxcyte by 5.8% in the first quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company's stock worth $362,000 after purchasing an additional 524 shares during the period. Parallel Advisors LLC increased its stake in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after purchasing an additional 1,071 shares during the period. Polar Asset Management Partners Inc. bought a new position in shares of Vaxcyte in the first quarter worth about $378,000. Finally, Raymond James Financial Inc. increased its stake in shares of Vaxcyte by 10.7% in the first quarter. Raymond James Financial Inc. now owns 293,134 shares of the company's stock worth $11,069,000 after purchasing an additional 28,430 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Trading Down 2.7%

PCVX traded down $0.89 on Friday, hitting $32.17. 1,465,354 shares of the stock traded hands, compared to its average volume of 1,406,471. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The firm has a market capitalization of $4.18 billion, a PE ratio of -7.83 and a beta of 1.04. The business has a fifty day moving average price of $33.16 and a two-hundred day moving average price of $39.28.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the previous year, the company posted ($1.10) earnings per share. On average, equities research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Cowen reiterated a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday. They issued a "neutral" rating and a $38.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and an average target price of $106.25.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.